Monalizumab
(Redirected from IPH2201)
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | NKG2A |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]
Mechanism of action
[edit]Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]
References
[edit]- ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- ^ IPH2201 studies
- ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
- ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
- ^ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
- ^ van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |